MedTrace Logo

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

NCT06988553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-12-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.

Conditions

Interventions

DRUG

AZD5004

AZD5004 will be administered as an oral tablet once daily.

DRUG

Placebo

Placebo will be administered as an oral tablet once daily.

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Principal Investigators

  • Eccogene · Eccogene Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-17
Primary Completion
2025-11-28
Completion
2025-11-28
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06988553 on ClinicalTrials.gov